Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China

BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune disorder with decreased platelet counts and increased bleeding risk. OBJECTIVES: To evaluate the efficacy and safety of avatrombopag, a second-generation oral thrombopoietin receptor agonist, for the treatment of Chinese patients with chroni...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Heng, Zhou, Hu, Hou, Ming, Sun, Jing, Zhang, Lei, Luo, Jianmin, Jiang, Zhongxing, Ye, Xu, Xu, Yajing, Lu, Jun, Wang, Hui, Hui, Aimin, Zhou, Yongchun, Hu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493258/
https://www.ncbi.nlm.nih.gov/pubmed/37700877
http://dx.doi.org/10.1016/j.rpth.2023.102158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493258/
https://www.ncbi.nlm.nih.gov/pubmed/37700877
http://dx.doi.org/10.1016/j.rpth.2023.102158

Ejemplares similares